Post-prandial secretion of glucagon-like peptide-2 (GLP-2) after carbohydrate-, fat- or protein enriched meals in healthy subjects

What Was Tested

Researchers studied GIP (Gastric Inhibitory Polypeptide) and Peptide YY in this randomized controlled trial publication.

Glucagon-like peptide 2 (GLP-2) is an important regulator of intestinal growth and function.

In adherable mixed meals the macronutrient composition with the best potential for stimulating GLP-2 secretion is not known.

How the Study Was Run

The researchers set it up as a randomized, open-label and crossover study.

Because people in this GIP (Gastric Inhibitory Polypeptide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Nothing was hidden in this open-label GIP (Gastric Inhibitory Polypeptide) study: the participants and staff both knew the treatment.

Each person switched between GIP (Gastric Inhibitory Polypeptide) and the comparison at some point, usually with a gap in between.

In an open-label, crossover design, they were randomized to receive a high carbohydrate (HC), high fat (HF) or high protein (HP) meal.

What Was Measured

Glucagon-like peptide 2 (GLP-2) is an important regulator of intestinal growth and function.

The subject headings attached to it are Carbohydrates, Gastric Inhibitory Polypeptide, Glucagon-Like Peptide 2, Healthy Volunteers, Meals, Nutrients and Peptide YY.

Author keywords: Glucose-dependent insulinotropic polypeptide and Post-prandial secretion.

What This Means in Plain Language

The paper is a randomized, open-label and crossover study of GIP (Gastric Inhibitory Polypeptide) and Peptide YY.

The publication is from 2023 (Peptides), a journal based in United States.

More context: the GIP (Gastric Inhibitory Polypeptide) compound page and the Peptide YY compound page, all human trials.